Orange Business is leveraging its expertise to support the Curie Institute in optimizing an artificial intelligence (AI) tool used by doctors. This partnership, initiated by an Orange Business employee affected by the disease, aims to improve the diagnosis of cancers of unknown origin and personalize their therapeutic approach.
In France, Institut Curie is the national coordinator of the multidisciplinary consultation meeting dedicated to cancers of unknown primary. Since its establishment in 2020, 442 patients have been enrolled in this RCP, and the number of enrollments continues to rise. Rare and complex, cancers of unknown primary are most often discovered at an advanced stage, through the presence of metastases, without being able to identify the primary organ involved in the pathology, complicating therapeutic treatment.
Orange Business data scientists are working on developing a module for better biological and clinical interpretation of the results provided by the AI, to better guide medical decisions. Orange Business is focusing on two areas: the visualization of results through the automatic generation of a report containing all patient information, and the explainability of AI decisions. This approach will highlight the genes contributing to each patient's diagnosis to enhance healthcare providers' trust in the technology used and the results obtained.
Claire Scotton, Vice President, B2B Healthcare, Orange Business
In the healthcare sector, the greatest advances often come from human encounters. This project is a perfect illustration of this. With the expertise of its 1,000 specialized healthcare experts and consultants, Orange Business is reaffirming its commitment to clinical research. Artificial intelligence is opening up revolutionary prospects for optimizing patient care. As a partner in the digital transformation of a vital sector, we are proud to support medical research.
